Intellia Therapeutics, INC 8-K filings

Intellia Therapeutics has appointed Edward Dulac as its new CFO, effective July 22, 2024, succeeding Glenn Goddard who will step down on June 30, 2024.

Intellia Therapeutics has appointed Brian Goff, a seasoned biopharmaceutical executive, to its board of directors, effective June 13, 2024.

Intellia Therapeutics amended its charter to limit officer liability and held its annual meeting, electing directors and ratifying the appointment of its accounting firm.

Intellia Therapeutics announced its first quarter 2024 financial results and provided updates on its clinical programs, including rapid enrollment in a Phase 3 trial and alignment with the FDA on another.

Intellia Therapeutics reports a 95% mean reduction in monthly angioedema attacks with its NTLA-2002 therapy, with 9 out of 10 patients remaining attack-free after a single dose.

Intellia Therapeutics has terminated its co-development agreement with Regeneron for Factor IX gene editing products, shifting to a licensing agreement for future development.

Intellia Therapeutics has increased its at-the-market offering program with Jefferies LLC from $400 million to $750 million, signaling a potential for further capital raising.

Intellia Therapeutics announced its fourth quarter and full-year 2023 financial results, highlighting progress in its CRISPR-based therapy programs and a strong cash position.

Intellia Therapeutics reports positive interim Phase 1 results for NTLA-2002, showing a 95% mean reduction in monthly hereditary angioedema attack rates.